George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tried to send the link but don’t seem to be opening
Whilst I was searching yahoo finance I noticed a add for Boots pop up. The add was focussed on the PCR tests etc available at Boots with Boots promoting them.This is clearly positive and Boots clearly have confidence in the MHC products and I believe we should also remain confident. The share price could move rapidly if positive news is formally released as regards new products prior to results. MHC spread is a negative but this could easily narrow. The next few weeks will be a major game changer for MHC if the board delivers on Covid revenue along with new product roll out. The key to investing in MHC is whether you believe MHC will be stronger in Years to come. Well if the last few years are anything to judge performance bye then the board are clearly demonstrating their ability to create value. With new strains of Covid being detected all the time and new things like Monkey Poxs that open opportunities at MHC I believe we well undervalued. This is just my opinion and I’m sure some will see it differently but I believe in the boards vision and MHCs fundamentals
I didn’t realise that, first time I’d found it.
*CRI genetics that should say
Looking at companies who offer similar-ish genetic testing (dnafit and cgi genetics) were two that I found, their offerings were >£100, although not exactly comparable as they seemed to offer more than just the intolerance testing in their base kit
That page has been like that for a year or two now. As far as I can remember, the tests that were leaked on the dev site are different to the ones on that live page. For example I'm sure there was a 'food intolerance' test on the dev site.
I'm interested to see how good the DNA tests are at 'diagnosing' food intolerance. The blood IgG tests that have been available for a long time are widely regarded as useless for intolerances (not to be confused with IgE tests for allergies). Hopefully the DNA intolerance tests prove a lot more useful.
FYI the 5 products are now on the main website, under the ‘DNA Testing’ tab next to the ‘Investors’ tab, stating that they will be ‘available soon’.
I’m interested to see the price point because I appreciate the test website showed them at £45 but Lloyds already has a range of self test products at £12.49, although Boots appears not to have anything of this type at the moment, so that’s where I see the first opportunity.